Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Operating Cash Flow

Cash generated by the company's core business operations during the period.

Omeros CorporationNASDAQ: OMER

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow declines year over year

Q1 FY2026 operating cash flow of $14.51M (cash outflow) fell 59.5% year over year, behind the -33.7% change in trailing-twelve-month operating cash flow. Sequentially, it fell 63.6% from the prior quarter. Over 3 fiscal years it compounded at +10.3% a year.

Context

  • Operating cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -59.5% toward the trailing-twelve-month pace of -33.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.51M-63.6% QoQ
Last fiscal yearDec 2025
-$116.09M-22.0% YoY
LTMMar 2026
-$94.76M-33.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-59.5%——
1 year-22.0%——
3-year CAGR+10.3%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(116.09M) USD
Year-over-year change
+22.0%

Operating Cash Flow vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 operating cash flow of $94.76M is the 6th largest of the 11 companies compared; the peer median is $124.3M.
  • Its year-over-year change of -33.7% is the lowest of 10, against a peer median of +22.4%.
  • Operating cash flow amounts to 957.8% of revenue for OMER, versus a peer median of 196.1%.
OMER Competitors Peer median
Operating Cash Flow for OMER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$511.4M -20.7%+27.0%—
RCUSArcus Biosciences, Inc.LTM Jun 2026$474M +39.8%—405.1%
NKTRNektar TherapeuticsLTM Jun 2026$233.79M +26.4%-11.8%428.3%
XNCRXencor, Inc.LTM Jun 2026$205.81M +53.4%—196.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$178.64M +18.9%+11.5%—
OMEROmeros CorporationLTM Mar 2026$94.76M -33.7%+10.3%957.8%
MGNXMacroGenics, Inc.LTM Mar 2026$69.96M +0.5%-2.3%44.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$34.91M +22.4%+6.7%—
MREOMereo BioPharma Group plcLTM Mar 2026$26.95M -18.7%-14.1%5390.8%
ANABAnaptysBio, Inc.LTM Mar 2026$4.48M +104.1%—1.9%
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
Peer median (excluding OMER) $124.3M+22.4%+2.2%196.1%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191.55M)(182.03M)(117.81M)(156.82M)(3.35M)
Depreciation & Amortization1.39M952K920K950K964K
Deferred Income Tax00000
Stock-Based Compensation0011.65M10.49M8.19M
Change in Working Capital(14.11M)(118.97M)247.42M29.74M33.72M
Accounts Receivables(34.31M)(175.07M)245.72M40.01M30.45M
Inventory00000
Accounts Payables14.64M(10.67M)000
Other Working Capital5.57M66.76M1.7M(10.27M)3.27M
Other Non-Cash Items94.54M213.56M(67.46M)(33.17M)(155.62M)
Operating Cash Flow(109.72M)(86.48M)74.73M(148.8M)(116.09M)
Capital Expenditures(277K)(113K)(426K)(165K)(65K)
Acquisitions (Net)125.99M0000
Purchases of Investments(32.01M)(429.05M)(1.02B)(987.39M)(185.31M)
Sales of Investments100M301.59M1.05B1.07B109.9M
Other Investing Activities0000240M
Investing Cash Flow193.71M(127.56M)27.45M82.22M164.52M
Debt Repayment(1.82M)123.83M(101.58M)(41.34M)(89.16M)
Common Stock Issued8.38M415K0046.99M
Common Stock Repurchased00(4.65M)(11.85M)0
Dividends Paid00000
Other Financing Activities(241K)0150K116.07M0
Financing Cash Flow6.32M124.25M(106.08M)62.88M(42.17M)
Effect of Forex Changes00000
Net Change in Cash90.31M(89.8M)(3.9M)(3.71M)6.26M
Free Cash Flow(110M)(86.6M)74.3M(148.97M)(116.16M)

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.